On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayMar 28, 2017 10:41 am

NetworkNewsBreaks – RXi Pharmaceuticals Corp. (NASDAQ: RXII) Strengthens RXI-109 Intellectual Property with New Patent in Japan; Shares Rise

RXi Pharmaceuticals (NASDAQ: RXII) shares are up more than 38% this morning after the company said it has been granted a patent by the Japan Patent Office for the composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment or prevention of fibrotic disorders. Fibrotic disorders covered include, but are not limited to, skin fibrosis and proliferative retinopathy. This patent includes RXI-109, the company’s lead clinical candidate, which is currently being evaluated in phase 2 clinical trials. The patent will expire in 2031. "The granting of this patent in Japan further strengthens RXi's intellectual property estate for…

Continue Reading

MondayMar 27, 2017 11:20 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: OBMP 18.17% – News: Exceeds sales projections for licensed products EMMD 10.43% – News: Acquires new online travel portal ICAD 9.61% – News: Receives pre-market FDA approval for PowerLook® Tomo Detection NXTD 9.46% – News: Enters LOI with Fit Pay, Inc. to combine businesses EKSO 8.55% – News: Presenting at the ProCore Groundbreak 2017 construction technology conference March 29-31 JTPY 6.38% – News: Posts Q4, FY 2016 results TROV 5.52% – News: Presenting at…

Continue Reading

MondayMar 27, 2017 11:20 am

NetworkNewsBreaks – DryShips, Inc. (NASDAQ: DRYS) Acquires Four Modern Newcastlemax Vessels

DryShips (NASDAQ: DRYS) this morning said that it has entered into agreements with unaffiliated third parties to acquire four modern Newcastlemax bulk carriers of approximately 206,000 DWT and with an average age of 3.0 years. Two of the vessels will be employed under time charter contracts, while the other two will trade in the spot market. DryShips will finance the total gross purchase price of approximately $124 million using cash on hand, and it expects to take delivery of the vessels before the end of June 2017. "We are very pleased to have increased the size of our drybulk fleet by…

Continue Reading

MondayMar 27, 2017 11:19 am

NetworkNewsBreaks – Foamix Pharmaceuticals (NASDAQ: FOMX) Shares Sink on Report of Topline Results from Phase 3 Trials for FMX101

Shares of Foamix Pharmaceuticals (NASDAQ: FOMX) dove 50% this morning following the company’s report of topline results from its two phase 3 clinical trials investigating FMX101 (Trial 04 and Trial 05) in patients with moderate-to-severe acne. The two co-primary endpoints were the absolute change in the number of inflammatory lesions (papules and pustules); and the proportion of patients achieving success at week 12, as defined by an Investigator's Global Assessment (IGA) score of "clear" or "almost clear" and at least a two-grade improvement from baseline at week 12. FMX101 did not demonstrate statistical significance of IGA success in Trial 04.…

Continue Reading

MondayMar 27, 2017 9:38 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Scheduled to Present at The MicroCap Conference on April 4

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for the Agent-Owned Cloud Brokerage®, this morning announced that its management team will be attending The MicroCap Conference in New York on Tuesday, April 4, 2017. The company is scheduled to present at 9:30 a.m. ET at the JW Marriott Essex House New York, which is located adjacent to Central Park in Manhattan. The EXPI team will also host one-on-one meetings with prospective investors throughout the day. A webcast of the company’s presentation will be made available at http://wsw.com/webcast/microcapconf3/expi for those who are unable to attend the event. For more information about…

Continue Reading

FridayMar 24, 2017 11:55 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 24, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ZAIS 47.73% – News: Posts Q4, FY 2016 results LKAI 23.07% – News: Three largest shareholders increased their holdings ADAC 16.00% – News: Secures contracts with two marquis clients EBIO 8.42% – News: Posts Q4, FY 2016 results TLRS 7.66% – News: Increases and extends private placement HDYN 6.21% – News: Reconvening annual stockholders meeting on April 19 ENCR 5.94% – News: Holding a conference call to discuss FY 2016 on April 13 FNJN…

Continue Reading

FridayMar 24, 2017 11:27 am

NetworkNewsBreaks – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Receives ‘Buy’ Rating, $12 PT

Aegis Capital recently issued a ‘Buy’ rating and price target of $12 on shares of Corbus Pharmaceuticals Holdings (NASDAQ: CRBP). The company’s fourth quarter was marked by positive data from its phase 2 study of anabasum (previously Resunab or JBT-101) for the treatment of systemic sclerosis showing clear signal of clinical benefit. On March 13, Corbus held a Research and Development day and said the anticipated data from the phase 2a study in cystic fibrosis is on schedule for announcement during March 2017. Aegis cited this data as a possible milestone to drive shares of the company’s stock. For more…

Continue Reading

FridayMar 24, 2017 11:25 am

NetworkNewsBreaks – R-Three Technologies, Inc. (RRRT) Suspends Operations; Triggers Sell-off

R-Three Technologies (OTC: RRRT) shares are down more than 80% mid-morning after the company announced the temporary suspension of its operations. The suspension is pending funding, in either debt or equity financing, to implement the company's business plan. The business plan is to produce a variety of products, such as interlocking asphalt bricks, using recycled asphalt shingles. "The company is attempting to secure a minimum of $200,000 in debt or equity financing. If we secure such level of funding, the Company will be in a position to continue to lay the foundation to implement our business plan. An additional $800,000…

Continue Reading

FridayMar 24, 2017 11:23 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $11 PT on Conatus Pharmaceuticals Inc. (NASDAQ: CNAT)

Aegis Capital recently reiterated a ‘Buy’ rating and price target of $11 on shares of Conatus Pharmaceuticals (NASDAQ: CNAT). The company’s recent exclusive option, collaboration and license agreement with Novartis (NYSE: NVS) for the global development and commercialization of its lead product emricasan is cited as a positive catalyst by Aegis. For more information, visit www.conatuspharma.com About Conatus Pharmaceuticals Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity…

Continue Reading

FridayMar 24, 2017 11:21 am

NetworkNewsBreaks – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) Issued ‘Buy’ Rating, $8 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $8 on shares of Ritter Pharmaceuticals (NASDAQ: RTTR). The company recently modified the primary endpoint of its phase 2b/3 clinical trial of RP-G28, following a meeting with the FDA, in hopes of being considered as a pivotal trial, which would shorten the time frame to approval and revenues.  The report by Aegis cites the anticipated release of results from the phase 2b/3 clinical trial of RP-G28, which is expected by the end of the month. For more information, visit www.ritterpharma.com About Ritter Pharmaceuticals Ritter Pharmaceuticals, Inc. develops novel therapeutic products…

Continue Reading

Contact us: 212.418.1217